A5036547171- Multiple Myeloma Research and Treatments
- RNA modifications and cancer
- Protein Degradation and Inhibitors
- Cancer-related molecular mechanisms research
- Ferroptosis and cancer prognosis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Complement system in diseases
- Research on Leishmaniasis Studies
- Peptidase Inhibition and Analysis
- Circular RNAs in diseases
- Cancer Immunotherapy and Biomarkers
Second Xiangya Hospital of Central South University
2025
Central South University
2025
Ningbo University
2024
Singapore General Hospital
2016
Multiple myeloma (MM) is an incurable plasma cell neoplasm with incidence of 100 patients per year in Singapore.Major advances have been made the diagnosis, risk stratifi cation and treatment MM recent past.The reclassifi a subset smouldering MM, based on high-risk biomarkers, development revised international staging system are among key new developments diagnosis staging.The use novel agent-based has resulted signifi cant improvements survival quality life many MM.Determining optimal...
Objective Multiple myeloma (MM) varies in clinical behavior, response to treatment and prognosis due the heterogeneity of disease. Data on association between immunoparesis status during nontransplant MM patients are limited.
ABSTRACT Background Immune biomarkers for non‐small‐cell lung cancer (NSCLC) are programmed death ligand 1 (PD‐L1) and tumor mutational burden (TMB). However, they cannot accurately predict the effectiveness of immunotherapy. Identifying appropriate that can differentiate between beneficiary groups is imperative. Methods We identified lipoprotein receptor–related protein 1B (LRP1B) mutation as a potential biomarker immunotherapy by analyzing clinical data, combined with bioinformatics...